With the slogan “Science Doesn't Slow Down, and Neither Should You”, Lonza invites its customers to subscribe to the company’s free scientific journal. Resource Notes™ provides updates on the latest scientific developments and research tools from Lonza.
New subscriptions received until 31 December 2013* will take part in the drawing of an original JURA®, a Swiss high-quality, automatic bean-to-cup coffee machine. Bioresearch scientists, who want to keep themselves up to speed, may sign up at www.lonza.com/coffee4me.
The journal for life science researchers is being published twice a year. Its editorial section includes News and Events, Scientific Papers, Product Highlights as well as a TechTalk column. Highlights of the recently published issue are white papers on:
• Nucleofection™ of Cryopreserved Dissociated Adult Rat Vascular Smooth Muscle Cells
• High-throughput Screening of Conditionally Immortalized Cells
• Asthma- and COPD-related Differential Gene Expression in Primary Human Lung Fibroblast
Read the current issue or find previous Resource Notes™ in our archive
About Lonza Pharma&Biotech - Bioscience Solutions
Lonza provides the pharma market with the tools life science researchers use to develop and test therapeutics, from basic research to final product release. Lonza’s bioscience products and services range from cell culture and discovery technologies for research, to quality control tests and software to ensure product quality. Lonza Bioscience Solutions serves research customers worldwide in pharmaceutical, biopharmaceutical, biotechnology and personal care companies, as well as academic and government research institutions. The company delivers physiologically relevant cell biology solutions, biomarker discovery services, technologies to understand compound action and complete solutions for rapid microbiology. Primary brands include BioWhittaker™, Clonetics™, FlashGel™, MetaPhor™, MycoAlert™, Nucleofection™, NuSieve™, PAGEr™, Poietics™ and SeaKem®.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited (“SGX-ST”). In 2012, the company had sales of CHF 3.925 billion. Further information can be found at www.lonza.com.
